(Q30414622)

21 June 2017

title

Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice (English)

1 reference

21 June 2017

0 references

0 references

Chang Zhou

1

1 reference

21 June 2017

Leilei Zhou

series ordinal

2

1 reference

21 June 2017

Ying-Hua Chen

series ordinal

3

1 reference

21 June 2017

language of work or name

English

0 references

publication date

21 March 2012

1 reference

21 June 2017

1 reference

21 June 2017

volume

30

1 reference

21 June 2017

issue

23

1 reference

21 June 2017

page(s)

3463-3469

1 reference

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Prospects for universal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Influenza A viruses: why focusing on M2e-based universal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Universal influenza A vaccine: optimization of M2-based constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Mast cell activators: a new class of highly effective vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Characterization of immunity induced by M2e of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Genetic control of immune responses to influenza A matrix 2 protein (M2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Epitope vaccine: a new strategy against HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Epitope-vaccine strategy against HIV-1: today and tomorrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

Candidate vaccine focused on a classical Swine Fever virus epitope induced antibodies with neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.021

10.1016/J.VACCINE.2012.03.021

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference